Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I

Muscle-specific RING finger protein 1 (MuRF1) is a sarcomere-associated protein that is restricted to cardiac and skeletal muscle. In skeletal muscle, MuRF1 is up-regulated by conditions that provoke atrophy, but its function in the heart is not known. The presence of a RING finger in MuRF1 raises the possibility that it is a component of the ubiquitin–proteasome system of protein deg-radation. We performed a yeast two-hybrid screen to search for interaction partners of MuRF1 in the heart that might be targets of its putative ubiquitin ligase activity. This screen identified troponin I as a MuRF1 partner protein. MuRF1 and troponin I were found to associate both in vitro and in vivo in cultured cardiomyocytes. MuRF1 reduced steady-state troponin I levels when coexpressed in COS-7 cells and increased degradation of endogenous troponin I protein in cardiomyocytes. The degradation of troponin I in cardiomyocytes was associated with the accumulation of ubiquitylated intermediates of troponin I and was proteasome-dependent. In vitro, MuRF1 functioned as a ubiquitin ligase to catalyze ubiquitylation of troponin I through a RING finger-dependent mechanism. In isolated cardiomyocytes, MuRF1 reduced indices of contractility. In cardiomyocytes, these processes may determine the balance between hypertrophic and antihypertrophic signals and the regulation of myocyte contractile responses in the setting of heart failure.

[1]  A. Goldberg,et al.  The ATP dependence of the degradation of short- and long-lived proteins in growing fibroblasts. , 1985, The Journal of biological chemistry.

[2]  O. Dapunt,et al.  Different intracellular compartmentations of cardiac troponins and myosin heavy chains: a causal connection to their different early release after myocardial damage. , 1998, Clinical chemistry.

[3]  K. Pelin,et al.  Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. , 2001, Journal of molecular biology.

[4]  D. Atar,et al.  Role of troponin I proteolysis in the pathogenesis of stunned myocardium. , 1997, Circulation research.

[5]  G. Reboldi,et al.  Prognostic significance of serial changes in left ventricular mass in essential hypertension. , 1998, Circulation.

[6]  Siegfried Labeit,et al.  Cardiac titin: an adjustable multi‐functional spring , 2002, The Journal of physiology.

[7]  K. Wennerberg,et al.  p68RacGAP Is a Novel GTPase-activating Protein That Interacts with Vascular Endothelial Zinc Finger-1 and Modulates Endothelial Cell Capillary Formation* , 2004, Journal of Biological Chemistry.

[8]  Titin as a modular spring: emerging mechanisms for elasticity control by titin in cardiac physiology and pathophysiology. , 2002 .

[9]  Eric Karsenti,et al.  Transient association of titin and myosin with microtubules in nascent myofibrils directed by the MURF2 RING-finger protein , 2002, Journal of Cell Science.

[10]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[11]  A. Goldberg,et al.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Granzier,et al.  Section: The Elastic Vertebrate Muscle Protein Titin; Titin as a modular spring: emerging mechanisms for elasticity control by titinin cardiac physiology and pathophysiology , 2002, Journal of Muscle Research & Cell Motility.

[13]  D. Glass,et al.  Molecular mechanisms modulating muscle mass. , 2003, Trends in molecular medicine.

[14]  R. Kopito,et al.  Aggresomes: A Cellular Response to Misfolded Proteins , 1998, The Journal of cell biology.

[15]  A. Ciechanover,et al.  Immunochemical analysis of the turnover of ubiquitin-protein conjugates in intact cells. Relationship to the breakdown of abnormal proteins. , 1982, The Journal of biological chemistry.

[16]  A. Goldberg,et al.  A possible explanation of myxedema and hypercholesterolemia in hypothyroidism: control of lysosomal hyaluronidase and cholesterol esterase by thyroid hormones. , 1981, Enzyme.

[17]  P. Pierre,et al.  Transient aggregation of ubiquitinated proteins during dendritic cell maturation , 2002, Nature.

[18]  D. Cyr,et al.  CHIP Is a U-box-dependent E3 Ubiquitin Ligase , 2001, The Journal of Biological Chemistry.

[19]  C. Gregorio,et al.  Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1 , 2002, The Journal of cell biology.

[20]  J. Metzger,et al.  Myofilament Calcium Sensitivity and Cardiac Disease: Insights From Troponin I Isoforms and Mutants , 2002, Circulation research.

[21]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[22]  B. Lardeux,et al.  Amino acid and hormonal control of macromolecular turnover in perfused rat liver. Evidence for selective autophagy. , 1987, The Journal of biological chemistry.

[23]  U. Schmidt,et al.  Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes. Rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. , 1997, Circulation research.

[24]  T. Hunter,et al.  The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. , 1999, Science.

[25]  A. Goldberg,et al.  Importance of the ATP-Ubiquitin-Proteasome Pathway in the Degradation of Soluble and Myofibrillar Proteins in Rabbit Muscle Extracts* , 1996, The Journal of Biological Chemistry.

[26]  A. Goldberg,et al.  A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Goldberg,et al.  The activation of protein degradation in muscle by Ca2+ or muscle injury does not involve a lysosomal mechanism. , 1986, The Biochemical journal.

[28]  D. Kass,et al.  Transgenic mouse model of stunned myocardium. , 2000, Science.

[29]  A. Goldberg,et al.  Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. , 1999, The Journal of clinical investigation.

[30]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[31]  P. Powers,et al.  Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency. , 1999, Circulation research.

[32]  B. Lorell,et al.  Left ventricular hypertrophy: pathogenesis, detection, and prognosis. , 2000, Circulation.

[33]  D. K. Arrell,et al.  Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. , 1999, Circulation research.

[34]  J. Mogensen,et al.  Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy , 2004, The Lancet.

[35]  J. Dice.  Molecular determinants of protein half‐lives in eukaryotic cells , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.